OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Ali on Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in R/R Multiple Myeloma

March 24th 2025

Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.

Dr Gluz on Predictive Biomarkers for pCR With De-Escalated Chemo in HER2+ Breast Cancer

March 24th 2025

Oleg Gluz, MD, discusses findings from subgroup analyses of the WSG-TP-II trial of neoadjuvant de-escalated chemotherapy in HER2-positive breast cancer.

Dr Randall on a Bioengineered Bone Marrow Matrix to Explore Osteosarcoma Progression and Metastasis

March 24th 2025

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

Dr Zonder on the Need for Increased Awareness in Multiple Myeloma

March 24th 2025

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Dr Gupta on Avelumab Maintenance Therapy in Advanced Urothelial Cancer With Diabetes

March 21st 2025

Shilpa Gupta, MD, discusses OS outcomes with first-line maintenance avelumab plus BSC in advanced urothelial carcinoma based on diabetes mellitus.

Dr Cho on Niraparib Rechallenge Plus Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

March 21st 2025

Hyun-Woong Cho, MD, PhD, discusses the efficacy of maintenance therapy with niraparib plus bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Dr Shah on Zamtocabtagene Autoleucel’s Favorable Safety Profile in R/R DLBCL

March 21st 2025

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

Dr Bryce on the Comparative Efficacy of ARPIs Regardless of Disease Volume or Timing of Metastases in mHSPC

March 21st 2025

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

Dr Fenske on the Benefit With Auto-HSCT in MRD-Positive Patients With MCL in First CR

March 21st 2025

Timothy S. Fenske, MD, MS, discusses survival outcomes in patients with MCL who remained MRD positive following consolidative auto-HCT.

Dr Rao on the Current Treatment Landscape in Localized Anal Cancer

March 21st 2025

Sheela Rao, MBBS, MD, FRCP, highlights the current treatment landscape in the localized anal cancer setting for anal cancer Awareness Day, March 21.

Dr Liu on SBRT and IMRT in Colorectal Cancer

March 20th 2025

Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.

Dr Bhat on the Influence of MPN Risk Stratification on Treatment Decision-Making

March 20th 2025

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

Dr Randall on Factors Influencing the Choice Between Systemic Therapy and Surgery in TGCT

March 20th 2025

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

March 19th 2025

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Garfall on the Inclusion Criteria for a Study Evaluating Ide-Cel in Myeloma After Suboptimal Transplant/Maintenance Response

March 19th 2025

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

Dr Coombs on the Need for Consensus to Define High-Risk CLL

March 19th 2025

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC

March 18th 2025

Marwan Fakih, MD, discusses the advancement of botensilimab/balstilimab–based combination therapies in microsatellite-stable colorectal cancer.

Dr Montero on the Rationale for Evaluating Zanidatamab/Evorpacept in HER2+ Metastatic Breast Cancer

March 18th 2025

Alberto Montero, MD, MBA, CPHQ, explains the rationale for evaluating zanidatamab plus evorpacept in HER2-expressing metastatic breast cancer.

Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

March 18th 2025

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer

March 18th 2025

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.